Therefore, this phenomenon indicates that G-1 agonist may be a suitable therapeutic candidate to treat GPER-induced obesity and reduce lipid deposition or even alleviate chronic diseases related to obesity, such as diabetes mellitus. The gene discussed is GPER1; the disease is Obesity.